Yiran Jiang
Rheumatology · Annapolis, MDNPI 1811484983
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 366 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,575, 4.8 times the $748 reported in 2023.
Across 366 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$821
- UCB, Inc.$809
- Amgen$773
- Johnson & Johnson$570
- Pfizer$470
- plus $3K from 23 others
What the payments were for
- Food & beverage$6,98497%
- Education$2423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,103 |
| Novartis | 34 | $821 |
| UCB, Inc. | 52 | $809 |
| Amgen | 40 | $773 |
| Johnson & Johnson(2 entities) | 16 | $570 |
| Pfizer | 27 | $470 |
| AstraZeneca(2 entities) | 21 | $468 |
| Aurinia Pharma U.S., Inc. | 16 | $284 |
| Lilly USA, LLC | 11 | $281 |
| ANI Pharmaceuticals, Inc. | 12 | $218 |
| Sandoz | 8 | $194 |
| Sobi, Inc | 3 | $162 |
| E.r. Squibb & Sons, L.L.C. | 8 | $162 |
| GSK | 6 | $150 |
| Genentech USA, Inc. | 7 | $114 |
| Fresenius Kabi USA, LLC | 3 | $93 |
| Invivyd Inc | 4 | $92 |
| Boehringer Ingelheim | 2 | $65 |
| Radius Health, Inc. | 3 | $63 |
| Tersera Therapeutics LLC | 2 | $59 |
| Kyowa Kirin, Inc. | 3 | $54 |
| Sanofi | 2 | $49 |
| Bioventus LLC | 1 | $42 |
| Almatica Pharma LLC | 1 | $32 |
| US Oncology Corporate, Inc. | 1 | $27 |
| Biocon Biologics Inc | 1 | $25 |
| Tonix Medicines, Inc. | 1 | $18 |
| Organon | 1 | $15 |
| Fidia Pharma USA Inc. | 1 | $14 |
How this compares
$7,226 in reported general payments places this provider in the 65th percentile of 173 rheumatology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 11 | $95,756 |
| Cosentyx SyringeSecukinumab | 11 | $84,332 |
| Adalimumab-Adaz(Cf) PenAdalimumab-Adaz | 12 | $15,245 |
| MethotrexateMethotrexate Sodium | 110 | $5,049 |
| Hydroxychloroquine Sulfate | 42 | $2,574 |
| Prednisone | 236 | $1,728 |
| Leflunomide | 17 | $1,288 |
| Allopurinol | 60 | $653 |
| Pantoprazole Sodium | 13 | $309 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Annapolis
- Ashok JacobAnnapolis$32K
- Mariam AmeriAnnapolis$22K
- Susan BergerAnnapolis$12K
- Heidi SamiAnnapolis$8K
- Sonie UpretiAnnapolis$6K
- Evan SiegelRockville$594K
- Donald ThomasGreenbelt$471K
- Edmund MaclaughlinEaston$410K
- Michelle PetriBaltimore$381K
- Herbert BarafWheaton$268K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.